Answers are grounded in this paper and cite their sources.
The nonpsychoactive phytocannabinoid, CBD, was recently approved by the Food and Drug Administration for the treatment of children with drug-resistant epilepsy. This milestone opens new avenues for cannabinoid research. In this Viewpoint, we provide an overview of recent progress in the field highlighting molecular insights into CBD's mechanism of action, as well as its therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Morales et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: